Exalenz Bioscience develops and commercializes systems that extract vital information for diagnostics from subtle changes in patients' exhaled breath using the company's BreathID technology platform.
The company's proprietary core technology enables medical specialists to easily identify and manage specific digestive and liver conditions while ensuring both clinical precision and patient comfort. The BreathID Hp is a clinically proven, easy, and accurate single-step urea breath test for diagnosing and monitoring H. pylori infection in adults.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Exalenz Bioscience Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
May 1, 2020
www.finsmes.com
Meridian Bioscience Acquires Exalenz Bioscience - FinSMEs
#Acquisition
Feb 19, 2020
www.globenewswire.com
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience;Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
#Acquisition
Feb 19, 2020
www.360dx.com
Meridian Bioscience to Buy Exalenz Bioscience for $49M